Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 6/2016

01-06-2016 | Original Article

Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis

Authors: C.-H. Chen, C.-L. Lin, C.-H. Kao

Published in: Osteoporosis International | Issue 6/2016

Login to get access

Abstract

Summary

Gastroesophageal reflux disease (GERD) with proton pump inhibitor (PPI) use is associated with an increased risk of osteoporosis. The risk of hip fracture is not increased in GERD patients with PPI use.

Introduction

The relationship between GERD with PPI treatment and the risk of osteoporosis is unclear. We aimed to determine the risk of developing osteoporosis in patients diagnosed with GERD.

Methods

Patients diagnosed with GERD and received PPI treatment between 2000 and 2010 were identified from the Longitudinal Health Insurance Database as the study cohort (n = 10,620), which was frequency matched with the comparison cohort (n = 20,738) sampled from the general population according to age, sex, index year, and comorbidities. Both cohorts were followed until the end of 2011. The risk of osteoporosis was evaluated in both groups by using Cox proportional hazards regression models.

Results

The GERD patients with PPI treatment had a greater incidence (31.4 vs 20.7 per 1000 person-year; crude hazard ratio [cHR] 1.51; 95 % confidence interval [CI] 1.40–1.63) and a higher risk (adjusted HR [aHR] 1.50; 95 % CI 1.39–1.62) of osteoporosis than that of the comparison cohort. However, the overall incidence of hip fracture was not different between the GERD with PPI use and the control cohorts (aHR 0.79; 95 % CI 0.53–1.18).

Conclusion

GERD with PPI use is associated with an increased risk of osteoporosis. The findings of our study do not support an increased risk of hip fracture in GERD patients treated with a PPI.
Literature
1.
2.
Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21:41–52CrossRefPubMed
3.
Kinsella K, Wan H (2009) International Population Reports, p 95/09–1, An aging world: 2008. US Census Bureau, US Government Printing Office, Washington, DC
4.
Xia WB, He SL, Xu L, Liu AM, Jiang Y, Li M, Wang O, Xing XP, Sun Y, Cummings SR (2012) Rapidly increasing rates of hip fracture in Beijing, China. J Bone Miner Res 27:125–129CrossRefPubMed
5.
Vakil N, van Zanten SV, Kahrlas P, Dent J, Jones R (2006) The Montrel definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101:1900–1920CrossRefPubMed
6.
7.
Bredenoord AJ, Pandolfino JE, Amout AJPM (2013) Gastro-oesophageal reflux disease. Lancet 381:1933–1942CrossRefPubMed
8.
Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ (2009) Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanisms rather than caustic acid injury. Gastroenterology 137:1776–1784CrossRefPubMed
9.
Oh TY, Lee JS, Ahn BO, Cho H, Kim WB, Kim YB, Surh YJ, Cho SW, Lee KM, Hahm KB (2001) Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats. Gut 49:364–371CrossRefPubMedPubMedCentral
10.
11.
Lim SL, Goh WT, Lee JM, Ng TP, Ho KY, Community Medicine GI Study Group (2005) Changing prevalence of gastroesophageal reflux with changing time: longitudinal study in an Asian population. J Gastroenterol Hepatol 20:995–1001CrossRefPubMed
12.
Wong WM, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL, Xia HH, Huang JQ, Chan CK, Lam SK, Wong BC (2003) Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 18:595–604CrossRefPubMed
13.
Chen M, Xiong I, Chen H, Xu A, He L, Hu P (2005) Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population-based study in South China. Scand J Gastroenterol 40:759–767CrossRefPubMed
14.
Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319–326CrossRefPubMedPubMedCentral
15.
Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83CrossRefPubMed
16.
Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904CrossRefPubMed
17.
18.
Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25:1439–1443CrossRefPubMedPubMedCentral
19.
Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P (2005) Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus. Am J Epidemiol 162:454–460CrossRefPubMed
20.
Menon S, Jayasena H, Nightingale P, Trudgill NJ (2011) Influence of age and sex on endoscopic findings of gastrooesophageal reflux disease: an endoscopy database study. Eur J Gastroenterol Hepatol 23:389–395CrossRefPubMed
21.
Achem SR, DeVault KR (2014) Gastroesophageal reflux disease and the elderly. Gastroenterol Clin N Am 43:147–160CrossRef
22.
Sossalla S, Schotola H, Schmitto J, Toischer K, Sihns C, Schworer H, Hasenfuss G, Maier L, Schillinger W (2011) Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium. J Cardiovasc Surg 52:437–444
23.
Khinchi P, Saha S, Saraf SA, Kaithwas G (2014) Combination therapy of gamma-aminobutyric acid derivative promotes proton pump inhibitor based healing of reflux esophagitis in animal model. Pharmacol Rep 66:165–168CrossRefPubMed
24.
Hall SD, Prokic EJ, McAllister CJ, Ronnqvist KC, Williams AC, Yamawaki N, Witton C, Woodhall GL, Stanford IM (2014) GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson’s disease. Neuroscience 281:68–76CrossRefPubMedCentral
25.
Sung HY, Park JW, Kim JS (2014) The frequency and severity of gastrointestinal symptoms in patients with early Parkinson’s disease. J Mov Disord 7:7–12CrossRefPubMedPubMedCentral
26.
Treiman DM (2001) GABAergic mechanisms in epilepsy. Epilepsia 42(suppl 3):8–12
27.
Zhang J, Cui PL, Lv D, Yao SW, Xu YQ, Yang ZX (2011) Gastroesophageal reflux in cirrhotic patients without esophageal varices. World J Gastroenterol 17:1753–1758CrossRefPubMedPubMedCentral
28.
Giorgio M, Trinei M, Migliaccio E, Pelicci PG (2007) Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Mol Cell Biol 8:722–728CrossRef
29.
Armas LAG, Recker RR (2012) Pathophysiology of osteoporosis. Endocrinol Metab Clin N Am 41:475–486CrossRef
30.
Ilic K, Obradovic N, Vujasinovic-Stupar N (2013) The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int 92:217–227CrossRefPubMed
31.
Bagger YZ, Rasmussen HB, Alexandersen P, Werge T, Christiansen C, Tanko LB, PERF study group (2007) Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int 18:505–512CrossRefPubMedPubMedCentral
32.
Pirih F, Lu J, Ye F, Bezouglaia O, Atti E, Ascenzi MG, Tetradis S, Demer L, Aghaloo T, Tintut Y (2012) Adverse effects of hyperlipidemia on bone regeneration and strength. JBMR 27:309–318CrossRef
33.
Nakchbandi IA, Osteoporosis and fractures in liver disease (2014) Relevance, pathogenesis and therapeutic implications. World J Gastroenterol 20:9427–9438PubMedPubMedCentral
34.
Weinstein RS (2012) Glucocorticoid-induced osteoporosis and osteonecrosis. Endocinol Metab Clin N Am 41:595–611CrossRef
35.
Pack AM, Morrell MJ (2004) Epilepsy and bone health in adults. Epilepsy Behav 5(suppl 2):S24–S29
36.
Hill DD, Cauley JA, Sheu Y, Bunker CH, Patrick AL, Baker CE, Beckles GLA, Wheeler VW, Zmuda JM (2008) Correlates of bone mineral density in men of African ancestry: the Tobago Bone Health Study. Osteoporos Int 19:227–234CrossRefPubMed
37.
Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, CaMos Research Group (2013) The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Study. Osteoporos Int 24:1161–1168CrossRefPubMed
38.
Hinson AM, Wilkerson BM, Rothman-Fitts I, Rggs AT, Stack BC, Bodenner DL (2015) Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc 63:2070–2073CrossRefPubMed
39.
Soloman DH, Diem SJ, Ruppert K, Lian YJ, Liu CC, Wohlfart A, Greendale GA, Finkelstein JS (2015) Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a Swan cohort study. JBMR 30:232–239CrossRef
40.
Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z (2010) Proton pump inhibitors use, hip fracture, and changes in bone mineral density in postmenopausal women. Arch Intern Med 170:765–771CrossRefPubMedPubMedCentral
41.
Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589CrossRefPubMed
42.
Armour KJ, Armour KE, van’t Hof RJ, Reid DM, Wei XQ, Liew FY, Ralston SH (2001) Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum 44:2790–2796CrossRefPubMed
43.
Sertorio JT (2013) Proton pump inhibitors and nitric oxide mechanisms in type 2 diabetes. Diabetologia 56:2763–2764CrossRefPubMed
44.
Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953CrossRefPubMed
Metadata
Title
Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis
Authors
C.-H. Chen
C.-L. Lin
C.-H. Kao
Publication date
01-06-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 6/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3510-1

Other articles of this Issue 6/2016

Osteoporosis International 6/2016 Go to the issue

Original Article

The epidemiology of fractures in Denmark in 2011

Original Article

Abdominal obesity and hip fracture: results from the Nurses’ Health Study and the Health Professionals Follow-up Study

Original Article

Combination of red cell distribution width and American Society of Anesthesiologists score for hip fracture mortality prediction

Original Article

Pre-fracture quality of life predicts 1-year survival in elderly patients with hip fracture—development of a new scoring system

Short Communication

The level of FoxO1 and IL-15 in skeletal muscle, serum and synovial fluid in people with knee osteoarthritis: a case control study

Original Article

Safety and clinical performance of kyphoplasty and SpineJack® procedures in the treatment of osteoporotic vertebral compression fractures: a pilot, monocentric, investigator-initiated study